Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-12-29 Declaration of Voting R…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for the company 'Addbiotech'. It details the resolutions passed, including the appointment of directors and changes to the company's business objectives. This falls under the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports the outcome of shareholder votes at a general meeting.
2025-12-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of a new outside director for the company Adbiotech. This falls directly under the category of Board/Management Information, which covers announcements regarding changes in the board of directors.
2025-12-29 Korean
[기재정정]주요사항보고서(유형자산양수결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the acquisition of tangible assets (유형자산 양수 결정) by Adbiotech. It is a regulatory filing submitted to the Korea Exchange (KRX) detailing a correction (정정신고) to a previously filed acquisition notice, specifically updating the payment date and asset transfer schedule. Since this is a formal regulatory disclosure of a material corporate event (asset acquisition) and does not fit into specific categories like M&A (which usually refers to company takeovers) or financial reports, it is classified as a general regulatory filing.
2025-12-26 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the amendment (정정신고) of a previous capital increase filing, specifically updating payment dates, listing dates, and allocation details. This falls under the category of announcements regarding new share issues or capital changes.
2025-12-24 Korean
타인에대한담보제공결정
Capital/Financing Update Classification · 98% confidence The document is a formal regulatory disclosure regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정) by the company Adbiotech. This type of filing is a standard corporate disclosure required by the Capital Markets Act in Korea for material events involving financial guarantees or collateral provided to subsidiaries. Since it does not fit into specific categories like M&A, dividends, or earnings, and is a formal regulatory announcement, it is classified as a Regulatory Filing (RNS).
2025-12-24 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Addbiotech) regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증결정). This is a specific corporate disclosure required by the Capital Markets Act in Korea for material financial events. Since it does not fit into specific categories like M&A, dividends, or earnings releases, and is a formal regulatory disclosure, it falls under the 'Regulatory Filings' category.
2025-12-24 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.